Aprea Therapeutics, INC Schedule 13G passive stakes

Laurence W. Lytton has updated his beneficial ownership filing for Aprea Therapeutics, Inc., reporting a 3.2% stake.

Vestal Point Capital and Ryan Wilder have filed a Schedule 13G reporting a 9.9% beneficial ownership stake in Aprea Therapeutics, Inc.

AIGH Capital Management and Orin Hirschman have reported a combined beneficial ownership of 9.9% in Aprea Therapeutics, Inc., primarily through warrants and common stock.

Squadron Master Fund LP, along with its investment advisor Squadron Capital Management LLC and partners William Blank and Matthew Sesterhenn, has reported beneficial ownership of approximately 9.9% of Aprea Therapeutics, Inc. common stock.

Soleus Private Equity and affiliated entities, including Guy Levy, have disclosed a 9.99% beneficial ownership stake in Aprea Therapeutics, Inc. through warrants.

Nantahala Capital Management and its principals have reduced their beneficial ownership in Aprea Therapeutics, Inc. to 4.50% as of December 31, 2025.

AIGH Capital Management LLC and Orin Hirschman reported a 9.9% beneficial ownership stake in Aprea Therapeutics, Inc. common stock as of December 31, 2025.

Laurence W. Lytton has increased his beneficial ownership in Aprea Therapeutics, Inc. to 9.9% of the common stock, following a purchase in an at-the-money offering.

Sio Capital Management, LLC has updated its beneficial ownership in Aprea Therapeutics, Inc., reporting a 1.93% stake as of September 30, 2025.

Sio Capital Management, LLC has filed an Amendment No. 3 to its Schedule 13G, reporting a 5.05% beneficial ownership stake in Aprea Therapeutics, Inc. as of June 30, 2025.

Stonepine Capital Management, LLC and its affiliates have filed an amended Schedule 13G, disclosing a 4.3% beneficial ownership stake in Aprea Therapeutics, Inc., totaling 239,416 shares.

Sio Capital Management, LLC has filed an amended Schedule 13G, reporting a beneficial ownership of 5.04% in Aprea Therapeutics, Inc.'s common stock as of March 31, 2025.

Stonepine Capital Management, LLC and its affiliates have filed an amended Schedule 13G, disclosing a 5.1% beneficial ownership stake in Aprea Therapeutics, Inc. as of December 31, 2024.

Sio Capital Management, LLC has reported a 5.09% beneficial ownership stake in Aprea Therapeutics, Inc. as of December 31, 2024, according to an amended Schedule 13G filing.

Investment firm AIGH Capital Management LLC and its managing member Orin Hirschman have reported a 9.9% beneficial ownership in Aprea Therapeutics, Inc. as of December 31, 2024.